Glyxambi
Marketed by: Boehringer Ingelheim Pharmaceuticals, IncIndication: The FDA has approved Glyxambi (empagliflozin and linagliptin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. The recommended dose is 10 mg empagliflozin/5 mg linagliptin once daily, taken in the morning, with or without food. Glyxambi should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.Dosage Form: Tablets: 10 mg/5 mg and 25 mg/5 mgFor More Information: www.glyxambi.comEylea
Marketed by: Regeneron Pharmaceuticals, IncIndication: The FDA has expanded the approved use of Eylea (aflibercept) to include the treatment of diabetic retinopathy in patients with diabetic macular edema. The recommended dosage for this indication is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks for the first 5 injections, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks. Eylea is also indicated for treating (1) neovascular (wet) age-related macular degeneration, (2) macular edema following central retinal vein occlusion, and (3) diabetic macular edema.Dosage Form: Single-use vial: 40 mg/ mL solution for intravitreal injectionFor More Information: www.eylea.usJadenu
Marketed by: Novartis Pharmaceuticals CorporationIndication: The FDA has approved Jadenu (deferasirox), an iron chelator, for the treatment of (1) chronic iron overload due to blood transfusions in patients 2 years and older and (2) chronic iron overload in nontransfusion-dependent thalassemia syndromes in patients 10 years and older. For the dosing guidelines, see the full prescribing information, which includes a black box warning for renal failure, hepatic failure, and gastrointestinal hemorrhage.Dosage Form: Tablets: 90, 180, and 360 mgFor More Information: www.jadenu.comSaphris
Marketed by: Actavis, IncIndication: The FDA has approved Saphris (asenapine) sublingual tablets as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder for patients aged 10 to 17 years. For the dosing guidelines, see the full prescribing information, which includes a black box warning for increased mortality in elderly patients with dementia-related psychosis. Saphris is also approved for the treatment of schizophrenia.Dosage Form: Sublingual tablets: 2.5, 5, and 10 mgFor More Information: www.saphris.com
